Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

RIGLAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.72+ 1.34%S&P 500 · SPY770.01+ 0.61%Dow Jones · DIA523.40+ 0.08%Russell 2000 · IWM280.14+ 1.14%

Rigel Pharmaceuticals Shares Rose Even As Profit Fell
If you only saw Rigel Pharmaceuticals’ latest quarterly results, with revenue and net income both lower than a year earlier and net margin compressed from 58.6% to 22.0%, you might assume shareholders had a rough ride. Investors who held Rigel Pharmaceuticals over the past year are up 66.2%, including dividends. If you were weighing an investment on 22 October 2025, what did the mix of pipeline promise and earnings quality really signal about taking that risk? Rigel Pharmaceuticals is not the...
Yahoo17:124 Days AgoRIGL+1.3%

06:00-09:00Oct 192 Stories

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO® (pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection (RET) fusion-positive solid tumors will be presented in a rapid oral session at the European Society For Medical Oncology (ESMO) Congress 2026 on Sunday, Octo
Yahoo08:05RIGL+1.3%
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $85 price target.
Benzinga06:50RIGL+1.3%

10:00Oct 131 Story

Reasons Why Investors Should Consider Betting on Arvinas Stock
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
Yahoo10:27